Cytotoxic chemotherapies for prolactin-secreting carcinomas, such as carboplatin and combinations like lomustine/5-fluorouracil, aim to induce tumor cell death by damaging DNA or inhibiting critical cellular processes; however, these treatments have resulted in only modest tumor responses and often require discontinuation due to significant hematological toxicity [1, 18]. This evidence concerns the gene PRL and neoplasm.